New venture round boosts Raven's cancer work

South San Francisco-based Raven biotechnologies has pocketed $48.3 million from its fourth round of venture capital. Vulcan Capital led the round. Raven has been working to develop monoclonal antibody therapeutics for treating cancer.

- read this press release for more

ALSO: Alinea Pharmaceuticals has raised $45 million in its first round of venture capital. MPM Capital Ventures led the round with Flagship Ventures and Burrill & Co. joining in. Alinea is working on a treatment for diabetic neuropathy, a condition involving nerve damage among diabetics. Private Equity Week reports that Alinea is already working on a second round of $25 million. Report

PLUS: Light Sciences Oncology has raised $35 million in its first round. Report

FINALLY: Aerie Pharmaceuticals raised $21 million in its first round. Release

Suggested Articles

Loretta Itri, M.D. has been helping Immunomedics out with its troubled antibody-drug conjugate. Now, she’s signing on as its chief medical officer.

Light Chain Bioscience, a unit of Swiss biotech Novimmune, has been handed a nice royalty milestone check from partner Takeda.

The fund received money from Chinese organizations inside and outside the biopharma industry, enabling CICC Capital to ease past its financing goal.